Immuron has developed and marketed colostrum-derived antibodies for prophylactic treatment of infectious diseases. This project will use the molecular skills of a Monash University research team to develop and evaluate the feasibility, in an animal model, of using similar technology for prevention of Clostridium difficile disease. This bacterium is a major global public health concern with a "superbug" strain emerging overseas, and recently in Victoria. There are currently no preventive and few effective, non-antibiotic, treatments available. The successful completion of this project may lead to a prophylactic antibody preparation that may be marketed in Australia and overseas, adding considerable value to an Australian platform technology.
|Effective start/end date||1/07/11 → 27/01/15|
- Australian Research Council (ARC): AUD495,000.00
- Immuron Limited: AUD268,901.00